

Division of Gynecologic Oncology
Fellow and Faculty Presentations and Publications

Presentations at Regional or National Meetings by Fellows (2011-2017)

Nagel CI, Denson W, Rogers P, Manders DB, Richardson DL, Kehoe SM, Miller DS, Lea JS. Survival impact of clinical trials in patients with recurrent cervical cancer [abstract]. In: Proceedings of the 40th Annual Meeting of the Western Association of Gynecologic Oncologists; 2011 Jun 16-18; Park City, UT.

Davidson B, **Nagel CI**, King M, Skorpinski T, Kehoe SM, Richardson DL, Miller DS, Lea JS. Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic Neoplasia [abstract]. In: Proceedings of the 40th Annual Meeting of the Western Association of Gynecologic Oncologists; 2011 Jun 16-18; Park City, UT.

Davidson B, **Nagel C**, Richardson D, Kehoe S, Miller D, Lea J. Challenging prognostic factors for chemotherapy resistance in gestational trophoblastic neoplasia [abstract]. In: Proceedings of the Forty-third Annual Meeting of the Society of Gynecologic Oncology; 2012 Mar 24-27; Austin, TX. p. 84. Abstract nr 201.

Elwell K, **Nagel C**, Lea J, Richardson D, Miller D, Kehoe S. Effect of BMI on progesterone therapy for endometrial cancer [abstract]. In: Proceedings of the Forty-third Annual Meeting of the Society of Gynecologic Oncology; 2012 Mar 24-27; Austin, TX. p. 163. Abstract nr 401.

Thomas S, **Nagel CI**, Richardson DL, Kehoe SM, Miller DS, Lea J. Incidence of adnexal metastasis requiring surgical intervention in women with advanced cervical [abstract]. In: Proceedings of the Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists; 2012 Jun 27-30; Huntington Beach, CA.

Bevan C, **Nagel CI**, Boren TP, Miller DS, Kehoe SM, Richardson DL, Albuquerque K, Lea J. Stage IIIC1 versus IIIC2 endometrial adenocarcinoma of the uterus: analysis of recurrence and patterns of toxicity [abstract]. In: Proceedings of the Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists; 2012 Jun 27-30; Huntington Beach, CA.

Nagel CI, Moron A, Elwell KE, Kehoe SM, Lea J, Miller DS, Richardson DL. Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus [abstract]. In: Proceedings of the Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists; 2012 Jun 27-30; Huntington Beach, CA.

Nagel CI, Street J, Kehoe SM, Richardson DL, Miller DS, Lea J. Clinical course of ovarian cancer after two salvage regimens [abstract]. In: Proceedings of the Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists; 2012 Jun 27-30; Huntington Beach, CA.

Nagel C, Davidson B, Elwell K, Bevan C, Kehoe S, Richardson D, Lea J, Miller D. #189 Assessment of the Accuracy of Preoperative and Intraoperative Endometrial Pathology in Uterine Carcinoma. [abstract] In: Proceedings of Society of Gynecologic Oncologists 44th Annual Meeting on Women's Cancer. Los Angeles, California March 2013. Gynecol Oncol 130;e1-e169, 2013.

Nagel C, Davidson B, Elwell K, Bevan C, Kehoe S, Richardson D, Lea J, Miller D. #190 Can Preoperative Factors Predict the Need for Postoperative Radiation in Patients with Endometrioid Adenocarcinoma of the Uterus? . [abstract] In: Proceedings of Society of Gynecologic Oncologists 44th Annual Meeting on Women's Cancer. Los Angeles, California March 2013. Gynecol Oncol 130;e1-e169, 2013.

Manders DB, Nagel CI, Conrad LB, Lin KY, Richardson DL, Kehoe SM, Miller DS, Lea JS. Total Laparoscopic Radical Hysterectomy in the Obese Patient. Poster Presentation. American Brachytherapy Society 2014 GYN School, Chicago, IL, July 12-14, 2014.

Manders DB, Miller DS, Richardson DL, Kehoe SM, Lea JS. Cervical Cancer – Distant Failure After Treatment of Para-Aortic Lymph Node Metastases. Oral Presentation. Western Association of Gynecologic Oncologists Annual Meeting, Truckee, CA, June 25-28, 2014.

Manders DB, Word RA, Lea JS. Differential Expression of Fibulin Proteins and Matrix Metalloproteinase 9 Enzyme Activity in Benign and Malignant Ovarian Tissue. Oral Presentation. Western Association of Gynecologic Oncologists Annual Meeting, Truckee, CA, June 25-28, 2014.

Manders DB, Paulsen A, Richardson DL, Kehoe SM, Miller DS, Lea JS. Factors Associated With Clinical Trial Screening Failures in Gynecologic Oncology. Poster Presentation. Society of Gynecologic Oncology Annual Meeting, Tampa, FL, March 22-25, 2014.

Moron A, **Manders DB**, Nagel CI, Miller DS, Richardson DL, Kehoe SM, Albuquerque K, Lea JS. [Outcomes of locally advanced cervical cancer in an underserved indigent US population](#). Poster Presentation. Society of Gynecologic Oncology Annual Meeting, Los Angeles, CA, March 9-12, 2013.

KL Lin MD, S Srivastava BS, DS Miller MD, SM Kehoe MD, DL Richardson MD, JS Lea MD. Adnexal Involvement in Clinical Stage I Endometrial Cancer American College of Surgeon (ACS) North Texas Chapter Annual Meeting, February 21-22, 2014, Dallas TX.

Ken Y. Lin, Shrikanth Gadad, Jayanthi S. Lea, W. Lee Kraus. Characterization of the Effects of Poly (ADP-Ribose) Polymerase-1 Inhibition on Transcription in Cervical Cancer. Cold Spring Harbor Meeting on the PARP Family & Friends: Gene Regulation and Beyond, April 9-12, 2014, Cold Spring Harbor, NY.

Ken Y. Lin, Jayanthi S. Lea, W. Lee Kraus. Bromodomain Inhibitor JQ1 as a Potential Therapeutic Agent for Squamous Cell Carcinoma of Cervix. American Brachytherapy Society Gynecologic Cancers Symposium / GYN School, July 12-14, 2014, Chicago, IL.

Lin KY, Bryant S, Miller DS, Richardson DL, Kehoe SM, Lea JS. Outcomes of Phenotypic Females with Dysgerminoma and 46, XY Karyotype. Western Association of Gynecologic Oncologists Annual Meeting, June 26 – 29, 2013, Seattle, WA.

Lin KY, Kehoe SM, Richardson DL, Miller DS, Lea JS. Ovarian Metastasis in Endometrial Adenocarcinoma of Uterus. Western Association of Gynecologic Oncologists Annual Meeting, June 25-28, 2014, Truckee, CA.

Conrad LB, Miller, DS, Kehoe S, Richardson R, and Lea JS, "Factors Influencing Primary Treatment in Advanced Vulvar Cancer" American Brachytherapy Society 2014 Meeting, Chicago, Illinois July 13-14, 2014.

Liu CS, Friel G, Kolomeyevskaya N, Lele S, Odunsi K, Moysich K. Aspirin and Acetaminophen Decrease the Risk of Cervical Cancer in Long-Term Users. Poster presented. Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, March 22-25, 2014.

Lin KY, Hechanova M, Richardson Debra, Kho, KA. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy For Benign Indications. 2015 ACOG Annual Clinical and Scientific Meeting, San Francisco, CA, May 2, 2015.

Manders DB, Albuquerque KV, Richardson DL, Kehoe SM, Miller DS, Lea JS. Emphasis on Systemic Therapy for Women with Pelvic Bone Involvement at Time of Diagnosis of Cervical Cancer. Poster Presentation. Western Association of Gynecologic Oncologists Annual Meeting, Santa Rosa, CA, June 10-13, 2015.

Conrad LB, Miller D, Kehoe S, Richardson D, Lea J. Defining optimal management of midline vulvar cancers. Oral Presentation. Western Association of Gynecologic Oncology Annual Meeting, Santa Rosa, CA, June 10-13, 2015.

Palavalli-Parsons LH, Manders DB, Richardson DL, Kehoe DM, Carlson M, Miller DS, Lea JS. Anti-Angiogenic Treatment of Cervical Cancer Significantly Decreases New Target Lesions. Poster Presentation. Western Association of Gynecologic Oncologists Annual Meeting, Santa Rosa, CA, June 10-13, 2015.

Palavalli Parsons LH, Miller D, Richardson D, Kehoe S, Carlson M, Lea J. Anti-Angiogenic Treatment of Cervical Cancer: Significant Tumor Regression with Severe Toxicity. Society of Gynecologic Oncology Annual Meeting on Women's Cancer, San Diego, California, March 19-22, 2016.

Conrad LB, Nandu T, Gibson BA, Lea JS, Kraus WL. Identification of distinct ADP-ribosylation patterns in ovarian cancer: a novel biomarker for therapy response. Featured Poster Presentation. Society for Gynecologic Oncology Annual Meeting, San Diego, California, March 19-22, 2016.

Khulpateea BR, Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Wolf JK, Munroe DG, Chon HS. Inbound referral patterns for ovarian cancer patients at a National Comprehensive Cancer Center (NCCN) institution. SGO 47th Annual Meeting, March 19-22, 2016, San Diego, CA. Abstract #6338.

Boac BM, Xiong Y, Marchion DC, Abbasi F, **Khulpateea BR,** McClung EC, Berry AL, Apte SM, Wenham RM, Lancaster JM, and Magliocco AM. Micro-RNAs associated with ovarian cancer in-vitro cisplatin-resistance regulate epithelial-mesenchymal transition. SGO 47th Annual Meeting, March 19-22, 2016, San Diego, CA. Abstract #6354.

McClung EC, Marchion DC, Abbasi F, Xiong Y, Boac BM, Robertson SE, Bush SH, **Khulpateea BR,** Lancaster JM, Magliocco AM. TGF/Wnt signaling: a metastasis signature for poor-prognosis ovarian cancer. Featured Poster. SGO 47th Annual Meeting, March 19-22, 2016 San Diego, CA. Abstract #6574.

Conrad LB, Nandu T, Gibson BA, Lea JS, Kraus WL. Identification of distinct ADP-ribosylation patterns and gene expression in ovarian cancer: relationship to clinical outcomes. The PARP Family and ADP-ribosylation, Cold Spring Harbor, New York, April 13-16, 2016.

Conrad LB, Awdeh H, Acosta-Torres, S, Conrad SA, Bailey AA, Lea JS. Defining sarcopenia in advanced ovarian cancer patients. American College of Obstetrics & Gynecology Annual Clinical and Scientific Meeting, Washington D.C., May 14-17, 2016.

Conrad LB, Awdeh H, Bailey AA, Miller DS, Lea JS. Core muscle index is prognostic of survival in advanced ovarian cancer. Oral presentation. Western Association of Gynecologic Oncology Annual Meeting, Sedona, AZ, June 8-11, 2016.

Liu CS, Roane B, Crim A, Moore K, Richardson D. The Role of Surgery in the Management of Stage IVB Endometrial Cancer. Poster presented. Western Association of

Gynecologic Oncologists Annual Meeting, Sedona, AZ, June 8-11, 2016.

Vandersluis A, Wade K, Ding K, Backes F, Cosgrove C, El Naggar A, Richardson D, **Liu C**, et al. A Multi-Institutional Analysis of Surgery and Chemotherapy for Stage IVB Uterine Carcinosarcoma. Poster presented Jan 26-28, 2017 at the Society of Gynecologic Oncology Annual Winter Meeting; Denver, CO.

Sims TT, **Palavalli Parsons LH**, Kehoe S, Richardson D, Miller D, Lea J, Carlson M. Close Incision Negative Pressure Therapy Should be Considered for Obese Patients Undergoing Laparotomy for Gynecologic Malignancies. Texas American College of Surgeons—Stronger Together Joint 2017 Annual Meeting, Austin, Texas, February 23-25, 2017

Palavalli-Parsons L, **Conrad LB**, Lea JS, Kraus WL. Characterization of PARP-7 in ovarian cancer cells. Society of Gynecologic Oncology 2017 Annual Meeting on Women's Cancer, National Harbor, MD, March 12-15, 2017

Palavalli Parsons LH, Pedersen R, Richardson DL, Kho KA. Risk of Occult Endometrial Cancer during Hysterectomy for Benign Indications. ACOG 2017 Annual Clinical and Scientific Meeting. San Diego, California, May 6-9, 2017.

Sims TT, **Palavalli Parsons LH**, Kehoe S, Richardson D, Miller D, Lea J, Carlson M. Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies. ACOG 2017 Annual Clinical and Scientific Meeting. San Diego, California, May 6-9, 2017.

Liu C, Sims T, Kehoe S. Risk-Reducing Salpingo-Oophorectomy for BRCA carriers: is there a benefit to combination procedures with breast surgery? Poster presented May 6-9, 2017 at the American College of Obstetricians and Gynecologists Annual Clinical Meeting; San Diego, CA.

Palavalli Parsons LH, Lin KY, Miller D, Richardson D, Carlson M, Kehoe S, Lea J. Family History of Cancer Shows Improved Survival in Uterine Papillary Serous Carcinoma. Western Association of Gynecologic Oncology 2017 Annual Meeting, Rancho Mirage, California, June 14-17, 2017.

Conrad LB, Schmidt S, Bailey AA, Carlson M, Kehoe S, Richardson D, Miller DS, Lea JS. Advanced Ovarian Cancer Patients with Sarcopenia Benefit from Neoadjuvant Chemotherapy. Western Association of Gynecologic Oncology Annual Meeting, Rancho Mirage, CA, June 14-17, 2017

Liu C, Spirtos A, Lea J. Correlations Between Stage and Survival When Comparing the International Federation of Gynecology and Obstetrics to the American Joint Committee on Cancer Staging Systems for Locally Advanced Cervical Cancer. Poster presented June 14-17, 2017 at the Western Association of Gynecologic Oncologists Annual Meeting;

Rancho Mirage, CA.

Fellow and Faculty Publications (2011-2017)

Salani R, Nagel CI, Drennen E, Bristow RE. [Recurrence patterns and surveillance for patients with early stage endometrial cancer](#). Gynecol Oncol. 2011 Nov;123(2):205-7.

Backes FJ, Nagel CI, Bussewitz E, Donner J, Hade E, Salani R. The impact of body weight on ovarian cancer outcomes. Int J Gynecol Cancer. 2011 Dec;21(9):1601-5.

Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A, Miller D, Maric D, Cedazo-Minguez A, Cookson MR. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet. 2011 Jan 1;20(1):40-50.

Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Miller DS, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011 Mar 1;29(7):825-31.

Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Apr;121(1):118-21.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 1;121(2):269-72.

Miller DS, Finnie J, Bowden TR, Scholz AC, Oh S, Kok T, Burrell CJ, Trinidad L, Boyle DB, Li P. Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine. J Gen Virol. 2011 May;92(Pt 5):1152-61.

Kehoe SM, Miller DS. The role of lymphadenectomy in endometrial cancer. Clin Obstet Gynecol. Clin Obstet Gynecol. 2011 Jun;54(2):235-44.

Tanner EJ, Black DR, Zivanovic O, Kehoe SM, Dao F, Konner JA, Barakat RR, Lichtman SM, Levine DA. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecol Oncol. 2012 Jan;124(1):59-62.

Boren TP, Carrick K, Kehoe SM, Lea J, Miller DS, Richardson DL. Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecol Oncol. 2012 Mar;124(3):508-11.

Seamon LG, Richardson DL, Copeland LJ. Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer. *Clin Obstet Gynecol*. 2012 Mar;55(1):131-55.

Garcia-Soto AE, **Boren T**, Wingo SN, Heffernen T, **Miller DS**. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? *Am J Obstet Gynecol*. 2012 Mar;206(3):e1-3.

Hallac RR, Ding Y, Yuan Q, McColl RW, **Lea J**, Sims RD, Weatherall PT, Mason RP. Oxygenation in Cervical Cancer and Normal Uterine Cervix assessed using BOLD MRI at 3 T. *NMR Biomed*. 2012 May 23. doi: 10.1002/nbm.2804. [Epub ahead of print]

Boren T, **Lea J**, Kehoe S, **Miller DS**, Richardson D. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. *Gynecol Oncol*. 2012 Jun 16. [Epub ahead of print]

Davidson B, **Nagel C**, Kehoe SM, Richardson DL, **Miller DS**, **Lea JS**. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent, Urban

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. *Gynecol Oncol*. 2012 Feb;124(2):221-4.

Boren TP, Carrick K, Kehoe SM, **Lea J**, **Miller DS**, Richardson DL. Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. *Gynecol Oncol*. 2012 Mar;124(3):508-11.

Garcia-Soto AE, **Boren T**, Wingo SN, Heffernen T, **Miller DS**. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? *Am J Obstet Gynecol*. 2012 Mar;206(3):242.

Boren T, **Lea J**, Kehoe S, **Miller DS**, Richardson D. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. *Gynecol Oncol*. 2012 Jun 16. [Epub ahead of print]

Davidson B, **Nagel C**, Kehoe SM, Richardson DL, **Miller DS**, **Lea JS**. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent, Urban Population. *The Journal of Reproductive Medicine*. Accepted for publication October 2013

Shields B, Pecot C, Potts M, **Nagel C**, Purinton S, Wang Y, Ivan C, Kim H, Borkowski R, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, **Lea J**, Gazdar A, Baggerly K, Sood A, White M. microRNA Induction of Fatal Differentiation Programs is a Common

Vulnerability in Ovarian Cancer. Accepted with revisions; Proceedings of the National Academy of Sciences of the United States of America (PNAS) March 2014.

Lin KY, Bryant S, **Miller DS**, Kehoe SM, Richardson DL, **Lea JS**. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. *Gynecol Oncol*. 2014 Jul;134(1):84-9

Manders DB, Paulsen A, Kehoe S, Richardson D, **Miller DS**, **Lea JS**. Factors Associated With Clinical Trial Screening Failures in Gynecologic Oncology. *Gynecol Oncol* 2014. In Press. doi: 10.1016/j.ygyno.2014.06.023

Nagel CI, Thomas S, Richardson DL, Kehoe SM, **Miller DS**, **Lea J**. Incidence of adnexal metastasis requiring surgical intervention in women with advanced cervical cancer. Accepted for publication. *Gynecologic Oncology*. Ms. No.: GYN-14-502R1

Nagel CI, Denson WN, Richardson DL, Kehoe SM, **Miller DS**, **Lea J**. Survival outcomes of clinical trials in patients with recurrent cervical cancer. *Clinical Ovarian and Other Gynecologic Cancer*. DOI: <http://dx.doi.org/10.1016/j.cogc.2014.06.004>

Shields B, Pecot C, Potts M, **Nagel C**, Purinton S, Wang Y, Ivan C, Kim H, Borkowski R, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, **Lea J**, Gazdar A, Baggerly K, Sood A, White M. microRNA Induction of Fatal Differentiation Programs is a Common Vulnerability in Ovarian Cancer. Accepted with revisions; Proceedings of the National Academy of Sciences of the United States of America (PNAS) March 2014.

Lin KY, Bryant S, **Miller DS**, Kehoe SM, Richardson DL, **Lea JS**. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. *Gynecol Oncol*. 2014 Jul;134(1):84-9

Manders DB, Paulsen A, Richardson DL, Kehoe SM, **Miller DS**, **Lea JS**. Factors associated with clinical trial screening failures in gynecologic oncology. *Gynecol Oncol*. 2014 Sep;134(3): 450-4.

Nagel CI, Thomas SK, Richardson DL, Kehoe SM, **Miller DS**, **Lea JS**. Adnexal masses requiring surgical intervention in women with advanced cervical cancer. *Gynecol Oncol*. 2014 Sep;134(3):552-5.

Manders DB, Paulsen A, Kehoe S, Richardson D, **Miller DS**, **Lea JS**. Factors Associated With Clinical Trial Screening Failures in Gynecologic Oncology. *Gynecol Oncol* 2014. In Press. doi: 10.1016/j.ygyno.2014.06.023

Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, **Miller DS**, Mutch DG, Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. *Gynecologic Oncology*. 2014 Dec;135(3): 441-5. doi: 10.1016/j.ygyno.2014.10.00

Nagel CI, Thomas S, Richardson DL, Kehoe SM, **Miller DS**, **Lea J**. Incidence of adnexal metastasis requiring surgical intervention in women with advanced cervical cancer. Accepted for publication. *Gynecologic Oncology*. Ms. No.: GYN-14-502R1

Nagel CI, Denson WN, Richardson DL, Kehoe SM, **Miller DS**, **Lea J**. Survival outcomes of clinical trials in patients with recurrent cervical cancer. *Clinical Ovarian and Other Gynecologic Cancer*. DOI: <http://dx.doi.org/10.1016/j.cogc.20>

Lin KY, **Miller DS**, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, **Lea JS**. Ovarian Involvement in Endometrioid Adenocarcinoma of Uterus. *Gynecol Oncol*. 2015.

Conrad LB, Ramirez PT, Burke W, Naumann RW, Ring KL, Munsell MF, Frumovitz M. Role of minimally invasive surgery in gynecologic oncology: an updated survey of members of the Society of Gynecologic Oncology. *International Journal of Gynecologic Cancer*. 2015 July;25(6):1121-7. PMID: 25860841

Ring KL, Ramirez PT, **Conrad LB**, Burke W, Naumann RW, Munsell MF, Frumovitz R. Make new friends but keep the old: minimally invasive surgery training in gynecologic oncology fellowship programs. *International Journal of Gynecologic Cancer*. 2015 Jul;25(6):1115-20. PMID: 26067857

Conrad LB, Groome LJ, Black DR. Management of persistent postpartum hemorrhage caused by inner myometrial lacerations. *Obstetrics & Gynecology*. 2015 Aug; 126(2):266-9. PMID: 25923024

Conrad LB. In Reply: Management of Persistent Postpartum Hemorrhage Caused by Inner Myometrial Lacerations. *Obstetrics & Gynecology*. 2015 Dec;126(6):1307-08. PMID: 26595565.

Friel G, **Liu CS**, Kolomeyevskaya et al. Aspirin and Acetaminophen Use and the Risk of Cervical Cancer. *J Low Genit Tract Dis*. 2015 Jul;19(3):189-93.

Hwang L, Bailey A, **Lea J**, Albuquerque K. Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management. *Future Oncol*. 2015 Jan;11(2):309-22.

Elshaikh MA, Al-Wahab Z, Mahdi H, Albuquerque K, Mahan M, Kehoe SM, Ali-Fehmi R, Rose PG, Munkarah A. Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: A multi-institution study. *Gynecol Oncol*. 2015 Feb;136(2):235-9.

Chong TW, Balch GC, Kehoe SM, Margulis V, Saint-Cyr M. Reconstruction of Large Perineal and Pelvic Wounds Using Gracilis Muscle Flaps. *Ann Surg Oncol*. 2015 Feb 24. Epub ahead of print

Monk BJ, **Miller DS**, Tewari KS. Reply to W.A.A. Tjalma and J.S. Grossman. *Journal of Clinical Oncology*. 2015 Mar 10;33(8): 966015. doi: 10.1200/JCO.2014.59.6205

Kunos C, Deng W, Dawson D, **Lea JS**, Zanotti KM, Gray HJ, Bender DP, Guaglianone PP, Carter JS, Moore KN. A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study. *Int J Gynecol Cancer*. 2015 Mar;25(3):484-92.

Fotopoulou C1, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, **Miller DS**, Marth C, Fujii S, Sehouli J. Surgical and systemic management of endometrial cancer: an international survey. *Arch Gynecol Obstet* 2015 Apr;291(4):897-905. doi: 10.1007/s00404-014-3510-3.

Davidson BA, Nagel CI, Richardson DL, Kehoe SM, **Miller DS**, **Lea JS**. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. *J Reprod Med*. 2015 May-Jun;60(5-6):243-8.

Lin KY, **Miller DS**, Bailey A, Andrews S, Kehoe S, Richardson D, **Lea JS**. Ovarian Involvement in Endometrioid Adenocarcinoma of Uterus. *Gynecol Oncol*. 2015 Jul 14. pii: S0090-8258(15)30073-1. doi: 10.1016/j.ygyno.2015.07.012. [Epub ahead of print]

Lin KY, **Miller DS**, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, **Lea JS**. Ovarian involvement in endometrioid adenocarcinoma of uterus. *Gynecol Oncol*. 2015 Sep;138(3):532-5. doi: 10.1016/j.ygyno.2015.07.012.

Pena CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, **Miller DS**, **Lea JS**, Wong KK, DeBerardinis RJ, Amelio AL, Brekken RA, Castrillon DH. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. *Journal of Clinical Investigation*. 2015 Nov;125(11):4063-76. doi: 10.1172/JCI82152

Pena C, Nakada Y, Saatcioglu D, Aloisio G, Cuevas I, Zhang S, **Miller D**, **Lea J**, Wong K, DeBerardinis R, Amelio A, Brekken R, Castrillion D. LKB1 loss promotes endometrial cancer progression via CCL2-dependent recruitment of macrophages. *J Clin Invest*. 2015 Nov 2;125(11):4063-76.

Albuquerque K, Folkert MR, Mayadev MS, Nagel C, Seval PR, Harkenrider MM, **Lea JS**, Hanna R, Small W, **Miller DS**, Potkul RK, Elshaik MA. Adjuvant External Radiation is essential in the management of pelvis limited stage III endometrial carcinoma. *International journal of radiation oncology, biology, physics*. 2015 Nov;93(3):S10-S11. DOI:10.1016/j.ijrobp.2015.07.031

Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, **Lea J**, Gazdar A, Baggerly KA, Sood AK, White MA. A genome-scale screen reveals

context- dependent ovarian cancer sensitivity to miRNA overexpression. *Mol Syst Biol.* 2015 Dec 11;11(12):842.

Lancaster JM, Powell CB, Chen L, Richardson, D. Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. *Gynecol Oncol* 2015;136:3-7.

Davidson BA, Nagel CI, Richardson DL, Kehoe SM, **Miller DS**, **Lea JS**. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent, Urban Population. *J Reprod Med.* 2015; 60:243-8.

Kho K, **Lin K**, Hechavova M, Richardson DL. Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. *Obstetrics and Gynecology.* 2016 Mar;127:468-73.

Albuquerque KA, Tumati V; Folkert M; Lawson S; Wise E; Wolcott S, Richardson, D; **Carlson M**, Kehoe S, **Lea J**, Abdulrahman R; Remote Location Interstitial Brachytherapy with Patient Stabilization and Subsequent Transport to an Outpatient Center for Treatment is Safe and Effective for the Treatment of Gynecologic Malignancies. *Brachytherapy.* 2016 Mar 19. pii: S1538-4721

Manders DB, Morón A, McIntire D, **Miller DS**, Richardson DL, Kehoe SM, Albuquerque KV, Lea JS. Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. *Am J Clin Oncol.* [In Press]. 2016 June 2.

Thu KL, Papar-Zareei M, Statsnu V, Song K, Peyton M, Martinez V, Zhang Y, Castri IB, Varella-arcia M, Liang H, Xing C, Kittler R, Michgrun S, Castrillion DH, Davidson HL, Reynolds CP, Lam WL, **Lea J**, Gazdar AF. A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. In Press. *OncoTarget.* June 2016. DOI: 10.18632/oncotarget.

Conrad LB, Conrad SA, **Miller DS**, Richardson DL, Kehoe S, **Lea JS**. Factors influencing primary treatment of midline vulvar cancers. *Gynecol Oncol.* 142(1):133-8, 2016 Jul.

Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, **Miller DS**. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. *Obstet Gynecol.* 128(3):535-42, 2016 Sep.

Liu C, Roane B, Crim A, Gillen J, Ding K, Moore K, Richardson D. The Role of Surgery in the Management of Stage IVB Endometrial Cancer. *Gynecologic Oncology.* 2016 Oct; 143:210.

Crim A, Gillen J, **Liu C**, Roane B, Ding K, Richardson D, Moore K. Prognostic Importance of Progression Free Survival Interval in Patients with IVB Endometrial

Cancer Treated with Platinum-Based Therapy. *Gynecologic Oncology*. 2016 Oct; 143:210

Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, **Miller DS**, Salani R, Moore DH, Stehman FB. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. *Gynecol Oncol*. 143(2):294-301, 2016 Nov.

Albuquerque K, Folkert M, Mayadev J, Christie A, Liotta MR, Nagel C, Sevak P, Harkenrider MM, **Lea JS**, Hanna RK, Small WC Jr, **Miller DS**, Xie XJ, Potkul RK, Elshaikh MA. Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study. *Am J Clin Oncol*. 2017 Feb 20. doi: 10.1097/COC.0000000000000371. [Epub ahead of print]

Bedell S, Manders D, Kehoe S, **Lea J**, **Miller D**, Richardson D, **Carlson M**. The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. *Gynecol Oncol*. 144(3):586-591, 2017 Mar. doi: 10.1016/j.ygyno.2016.12.022.

Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, **Miller DS**. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. *Gynecol Oncol*. 2017 Jun;145(3):519-525. doi: 10.1016/j.ygyno.2017.03.017.

Lea J, Sharma R, Yang F, Zhu H, Ward E, Schroit AJ. Detection of phosphatidyl serine positive exosomes as a diagnostic marker of ovarian malignancies – a proof of concept study. *Oncotarget*. In Press Jan 2017.

Conrad LB, Nandu T, Gibson BA, **Lea JS**, Kraus WL. Identification of distinct ADP-ribosylation and gene expression in ovarian cancer: relationship to clinical outcomes (manuscript in progress).

Conrad LB, Awdeh H, Bailey AA, **Miller DS**, **Lea J**. Change in core muscle index is prognostic of survival in advanced ovarian cancer (manuscript in progress).

Conrad LB, Awdeh H, Acosta-Torres S, Bailey AA, **Miller DS**, **Lea J**. Pre-operative hypoalbuminemia and sarcopenia: marker of inflammation and predictor of survival in advanced ovarian cancer (manuscript in progress).

Gibson BA, **Conrad LB**, Kraus WL. ADP-ribosylation detection reagents as diagnostic tools (manuscript in progress).